Paul J. Converse

This paper identifies DDU384, a new compound with potent in vivo efficacy against tuberculosis in murine models, showing potential to improve current treatment options.

This study evaluates TBD09's contribution to BPa-based tuberculosis regimens in mice, showing comparable bactericidal and sterilizing activity to linezolid with reduced toxicity.

This study evaluates telacebec's contribution to combination therapies against two M. tuberculosis strains in a murine model, finding synergistic effects against HN878 and antagonistic effects against H37Rv.

This study evaluates direct inhibitors of InhA (DIIs) for tuberculosis treatment, showing their efficacy comparable to isoniazid and their potential in new drug regimens.